United States Health

CervoMed (NASDAQ:CRVO) announced that neflamapimod will be featured in a late-breaking oral presentation at the International Society of Frontotemporal Dementias Annual Meeting in October 2026.

Burning Rock Biotech (NASDAQ:BNR) reported second-quarter 2026 revenue of RMB134.7 million, down 9.3% year over year, with net loss increasing to RMB18.4 million.

Axogen (NASDAQ:AXGN) agreed to acquire BioCircuit Technologies for $200 million in cash, adding the FDA-approved NerveTape™ device for sutureless peripheral nerve repair.

Disc Medicine (NASDAQ:IRON) reported initial Phase 2 RESTORE-PV results for DISC-3405, showing reduced phlebotomy requirements and stable hematocrit levels in patients with polycythemia vera.

Tyra Biosciences (NASDAQ:TYRA) reported initial Phase 2 SURF302 results showing oral dabogratinib achieved a 79% overall response rate at the 60 mg once-daily dose in FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer.

MannKind (NASDAQ:MNKD) and Rose Pharma entered a worldwide licensing and collaboration agreement to develop ROSE-010 Technosphere, an investigational inhaled GLP-1 therapy for weight management.

IDEAYA Biosciences (NASDAQ:IDYA) dosed the first patient in its Phase 3 OptimUM-11 trial to evaluate darovasertib as a first-in-class adjuvant therapy for primary uveal melanoma.

BridgeBio Pharma (NASDAQ:BBIO) reported exploratory Phase 3 PROPEL 3 data showing 52 weeks of oral infigratinib treatment produced favorable trends versus placebo in children with achondroplasia.

Evotec (NASDAQ:EVO) initiated a first-in-human Phase 1 trial of JST-018, an investigational monoclonal antibody cocktail targeting orthopoxviruses developed by its Just – Evotec Biologics subsidiary.

BioVie (NASDAQ:BIVI) advanced regulatory discussions with the U.S. FDA for a Phase 3 development program evaluating bezisterim in Parkinson’s disease following Phase 2 SUNRISE-PD results.

Inhibrx Biosciences (NASDAQ:INBX) reported Phase 2 HexAgon trial results showing INBRX-106 combined with pembrolizumab achieved a 48.3% confirmed objective response rate in first-line head and neck cancer patients.

Abbott (NYSE:ABT) received U.S. FDA approval for its TactiFlex Duo Ablation Catheter, Sensor Enabled, a device designed to treat atrial fibrillation using pulsed field ablation and radiofrequency energy technologies.